Affinage

Showing CPSF3YSH1 is a alias.

CPSF3

Cleavage and polyadenylation specificity factor subunit 3 · UniProt Q9UKF6

Length
684 aa
Mass
77.5 kDa
Annotated
2026-06-09
42 papers in source corpus 25 papers cited in narrative 25 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CPSF3 (CPSF-73) is the catalytic endoribonuclease of the eukaryotic pre-mRNA 3'-end processing machinery, executing the endonucleolytic cleavage at poly(A) sites that defines mRNA 3'-ends (PMID:17128255, PMID:15037765). Its catalytic core is a metallo-β-lactamase domain joined to a β-CASP domain, with a metal-ion active site at their interface; the enzyme uses a mixture of Fe, Zn and Mn ions rather than zinc exclusively, and active-site mutations that disrupt metal coordination abolish activity (PMID:17128255, PMID:36822327). CPSF3 acts together with CPSF100, whose conserved metallo-β-lactamase residues are also required for cleavage, the two subunits forming the active endonuclease, and its C-terminal CTD3 domain binds Symplekin to assemble the core cleavage complex (PMID:18688255, PMID:37989222). Beyond polyadenylation, CPSF3 is the dual endonuclease/5'-3' exonuclease of histone pre-mRNA 3'-end processing within the U7 snRNP, where it is recruited via a FLASH/Lsm11 platform and a symplekin N-terminal domain and is positioned for catalysis by direct Lsm11 contacts to its metallo-β-lactamase domain (PMID:16213211, PMID:18955505, PMID:23071092, PMID:32554553, PMID:41495886). CPSF3-mediated cleavage is foundational for RNA polymerase II transcription termination, acting upstream of Xrn2-dependent cotranscriptional degradation, and its loss produces extensive readthrough transcription and R-loop accumulation (PMID:29432121, PMID:31819276). CPSF3 protein levels are set by ubiquitin-dependent control: UBE3D acts as a cytoplasmic chaperone/stabilizer and RBBP6 mediates stabilizing K63-linked ubiquitination that also tunes alternative polyadenylation (PMID:35992060, PMID:39032490, PMID:38503731). CPSF3 is the direct molecular target of the inhibitors JTE-607 and active-site-binding benzoxaboroles/oxaboroles, which block its endonuclease activity (PMID:31399191, PMID:31819276, PMID:31694928, PMID:37967558).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 2004 High

    Established which factor contacts the pre-mRNA cleavage site and that cleavage is metal-dependent, pointing to a metallo-β-lactamase endonuclease.

    Evidence Site-specific UV-crosslinking in HeLa nuclear extract, yeast active-site mutant lethality, and metal-dependence assays

    PMID:15037765

    Open questions at the time
    • Did not directly demonstrate purified recombinant nuclease activity
    • Active-site architecture not yet resolved structurally
  2. 2005 High

    Identified CPSF-73 as the U7 snRNP-dependent factor contacting the histone pre-mRNA cleavage site, implicating one enzyme in both endo- and exonucleolytic steps.

    Evidence UV-crosslinking with site-specific RNA substrates plus immunoprecipitation

    PMID:16213211

    Open questions at the time
    • Crosslinking does not prove catalysis
    • Exonuclease role still inferred, not reconstituted
  3. 2006 High

    Resolved the catalytic basis of CPSF3 by showing a metallo-β-lactamase/β-CASP fold with a two-metal active site and reconstituting endonuclease activity, settling that CPSF3 is the 3'-processing nuclease.

    Evidence 2.1 Å crystal structure, recombinant in vitro endonuclease assay, active-site mutagenesis

    PMID:17128255

    Open questions at the time
    • Did not address how the enzyme is positioned within larger processing complexes
    • Exonuclease activity not structurally explained
  4. 2006 Medium

    Showed that a non-catalytic CPSF3 C-terminal region (via the yeast ortholog) is essential for processing and is a target of negative regulation, revealing functional roles beyond the catalytic domain.

    Evidence Yeast deletion genetics and in vitro 3'-end processing with extracts

    PMID:16431986

    Open questions at the time
    • Yeast ortholog; human C-terminal regulation not directly tested here
    • Molecular function of the C-terminus left undefined
  5. 2008 High

    Demonstrated that CPSF73 and CPSF100 metallo-β-lactamase residues both contribute, defining the endonuclease as a two-subunit unit rather than CPSF73 alone.

    Evidence Systematic MBL-residue mutagenesis of both subunits with histone pre-mRNA cleavage assays

    PMID:18688255

    Open questions at the time
    • Did not resolve the heterodimer interface structurally
    • Relative catalytic contribution of each subunit unquantified
  6. 2008 High

    Established CPSF-73 as the in vivo processive 5'-3' exonuclease degrading the downstream cleavage product, distinguishing it from Xrn2 for this step.

    Evidence UV-crosslinking, in vitro U7 snRNP degradation assays, Xrn2 RNAi

    PMID:18955505

    Open questions at the time
    • Structural basis of switching between endo- and exonuclease modes unresolved
  7. 2008 Medium

    Identified a regulatory partner (CSR1) that re-localizes CPSF3 to the cytoplasm and inhibits polyadenylation, linking CPSF3 activity to subcellular sequestration and cell death.

    Evidence Yeast two-hybrid, Co-IP, fractionation, in vitro/in vivo polyadenylation assays, siRNA

    PMID:18806823

    Open questions at the time
    • Single-lab finding without reciprocal structural mapping
    • Physiological context of CSR1 regulation unclear
  8. 2009 High

    Defined the CPSF73-CPSF100-Symplekin core subcomplex shared between poly(A) and histone machineries and showed cotranscriptional association with target genes.

    Evidence Reciprocal Co-IP, ChIP, RNAi with processing readouts

    PMID:19450530

    Open questions at the time
    • Stoichiometry and architecture of the core complex not resolved
    • Mechanism of switching between two machineries unaddressed
  9. 2012 High

    Showed that FLASH/Lsm11 N-terminal regions form the platform recruiting CPSF subunits including CPSF73 to U7 snRNP, defining the recruitment route for histone processing.

    Evidence Co-IP, pulldowns, mass spectrometry, FLASH/Lsm11 mutagenesis, chromatin assays

    PMID:23071092

    Open questions at the time
    • Did not place CPSF73 catalytic geometry within the assembled complex
  10. 2018 High

    Established that CPSF73 catalytic cleavage is required for and upstream of Pol II transcription termination, making it more foundational than Xrn2.

    Evidence Auxin-inducible degron depletion, catalytic-mutant rescue, genome-wide mNET-seq

    PMID:29432121

    Open questions at the time
    • Did not define how readthrough relates to R-loop formation
    • Termination defect mechanism downstream of cleavage incomplete
  11. 2019 High

    Identified CPSF3 as the direct target of small-molecule inhibitors (JTE-607, oxaboroles) that block processing, validating it as a druggable node and confirming functional consequences of inhibition.

    Evidence Affinity chromatography, phenotypic/chemical-genetic screening, resistance mutation mapping, pre-mRNA accumulation and R-loop assays, inhibitor crystal structure (Cryptosporidium ortholog)

    PMID:31399191 PMID:31694928 PMID:31819276

    Open questions at the time
    • Selectivity over related β-CASP nucleases not fully defined
    • Human inhibitor co-structure inferred partly from parasite ortholog
  12. 2019 Medium

    Showed that CPSF3 protein abundance is actively regulated via partner interactions and recruitment in yeast, connecting Ysh1 levels to global termination and poly(A) site selection.

    Evidence Yeast ChIP, genetic suppression by Ysh1 overexpression, Pol II elongation kinetics

    PMID:30759400

    Open questions at the time
    • Yeast ortholog; human Ipa1 equivalent not tested
    • Direct mechanism of Ysh1 destabilization not defined here
  13. 2020 High

    Achieved full recombinant reconstitution of U7 snRNP, proving CPSF73 carries both endo- and exonuclease activities and that symplekin NTD and SSU72 binding gate these activities.

    Evidence 13-component recombinant U7 snRNP reconstitution, cleavage/degradation assays, CPSF73 active-site mutagenesis

    PMID:32554553

    Open questions at the time
    • Structural snapshot of the active enzyme within the assembled complex not yet obtained
  14. 2020 Medium

    Demonstrated ubiquitin-proteasome control of CPSF3 stability in yeast, identifying the conjugating enzyme and ligase that target the nuclease.

    Evidence Yeast ipa1-1 mutant, proteasome inhibition, ubiquitination assays, overexpression rescue

    PMID:32009536

    Open questions at the time
    • Mammalian conservation of Ubc4/Mpe1 axis not established here
  15. 2021 Medium

    Identified UBE3D as a stabilizer that protects CPSF73 from proteasomal degradation, linking E3-ligase machinery to processing competence in human cells.

    Evidence UBE3D depletion, ubiquitination and protein stability assays, pre-mRNA cleavage readout

    PMID:35992060

    Open questions at the time
    • Direct enzymatic relationship of UBE3D to CPSF73 ubiquitin chains unresolved at this stage
  16. 2023 High

    Refined the metal identity and the C-terminal interaction module, showing the active site uses a Fe/Zn/Mn mixture and that CTD3 mediates Symplekin binding within a CPSF73-CPSF100 heterodimer.

    Evidence ICP-MS and anomalous X-ray scattering with activity assays; NMR of CPSF73-CPSF100 C-terminal heterodimer plus binding assays (parasite ortholog)

    PMID:36822327 PMID:37989222

    Open questions at the time
    • Physiological metal occupancy in cells uncertain
    • Heterodimer structure from parasite minimal construct
  17. 2023 High

    Provided a distinct inhibitor-bound active-site structure and resistance map, advancing structure-guided inhibition of CPSF73 endonuclease activity.

    Evidence X-ray crystallography of CPSF3-benzoxaborole complex, forward-genetics resistance screen, in vitro endonuclease and cellular termination assays

    PMID:37967558

    Open questions at the time
    • In vivo therapeutic window and selectivity not defined here
  18. 2024 Medium

    Showed two complementary ubiquitin-pathway mechanisms set CPSF3 levels: UBE3D acts as a cytoplasmic chaperone coordinating the active-site metals, while RBBP6 deposits stabilizing K63 chains that tune alternative polyadenylation.

    Evidence Co-IP, depletion with processing readout, structural analogy from INTS9-INTS11-BRAT1 cryo-EM (UBE3D); CRISPR screens, K63-ubiquitination assay, APA/3'UTR profiling (RBBP6)

    PMID:38503731 PMID:39032490

    Open questions at the time
    • Direct CPSF73-UBE3D structure inferred from paralog complex
    • How RBBP6 stabilization integrates with UBE3D chaperoning unresolved
  19. 2025 Medium

    Connected CPSF3 stability control by UBE3D to a developmental output, linking CPSF3-dependent processing to Homeobox gene expression in embryogenesis.

    Evidence Co-IP, CRISPR knockout mice, in situ hybridization, RNA-seq, dominant-negative CPSF3 overexpression

    PMID:40075082

    Open questions at the time
    • Whether UBE3D de-ubiquitinates or stabilizes CPSF3 mechanistically remains to be reconciled across studies
    • Direct gene-by-gene processing effects not mapped
  20. 2026 High

    Resolved how CPSF73 is held in catalytic position by Lsm11 contacts and showed it can adopt an active open conformation independent of RNA, plus revealed regulation of cleavage activity by RBBP6 and stress-responsive CTD phosphorylation.

    Evidence Cryo-EM of reconstituted U7 snRNP with mutagenesis and cleavage assays; nascent RNA sequencing with RBBP6 overexpression rescue and Pol II CTD ChIP under heat shock

    PMID:41495886 PMID:41758649

    Open questions at the time
    • Mechanism by which heat shock inactivates CPSF73 cleavage despite its presence not fully defined
    • How RBBP6 acts as cleavage activator at the catalytic step unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how CPSF3 dynamically switches between endonuclease and exonuclease modes and between poly(A) versus histone machineries, and how its ubiquitin-based stability control, metal loading, and conformational gating are integrated in cells.
  • No structural model of mode-switching within an assembled complex
  • Integration of UBE3D chaperoning, RBBP6 ubiquitination, and metal occupancy in vivo unknown
  • Determinants of activity loss under stress undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140098 catalytic activity, acting on RNA 7 GO:0003723 RNA binding 4 GO:0016787 hydrolase activity 2
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2
Pathway
R-HSA-392499 Metabolism of proteins 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-8953854 Metabolism of RNA 3
Complex memberships
CPSF (cleavage and polyadenylation specificity factor)CPSF73-CPSF100-Symplekin core cleavage complexU7 snRNP

Evidence

Reading pass · 25 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2006 CPSF-73 (CPSF3) is the pre-mRNA 3'-end-processing endonuclease. Crystal structure at 2.1 Å resolution revealed a metallo-β-lactamase domain and a novel β-CASP domain with a two-zinc-ion active site at their interface. Purified recombinant CPSF-73 possesses RNA endonuclease activity, and mutations disrupting zinc binding in the active site abolish this activity. X-ray crystallography (2.1 Å), in vitro RNA endonuclease assay with recombinant protein, active-site mutagenesis of zinc-coordinating residues Nature High 17128255
2005 CPSF-73 is both the endonuclease and the 5'-3' exonuclease in histone pre-mRNA 3'-end processing. UV-crosslinking with site-specifically labeled RNA substrates (at the cleavage site) identified an ~85 kDa protein that crosslinked in a U7 snRNP-dependent manner; immunoprecipitation identified this as CPSF-73. UV-crosslinking with site-specific radiolabeled/phosphorothioate RNA substrates, immunoprecipitation Cell High 16213211
2004 CPSF-73 contacts the pre-mRNA cleavage site in an AAUAAA-dependent manner, and mutation of key residues in the yeast CPSF-73 homolog (metallo-β-lactamase domain) causes lethality. The 3'-cleavage reaction is metal (Zn2+)-dependent, consistent with CPSF-73 being a metallo-β-lactamase-family endonuclease. UV-crosslinking with site-specific labeling in HeLa nuclear extract, yeast lethality assay with active-site mutants, metal-dependence assay (chelation/rescue) RNA (New York, N.Y.) High 15037765
2009 CPSF73, CPSF100, and Symplekin form a stable core subcomplex that associates with histone-specific processing factors and is required for histone pre-mRNA 3'-end processing; chromatin immunoprecipitation showed that CPSF73 and Symplekin (but not CstF50) cotranscriptionally associate with histone genes. This core complex can function in two alternative cleavage machineries (poly(A) and histone mRNA). Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), RNAi knockdown with functional pre-mRNA processing readout Molecular cell High 19450530
2008 Conserved residues in the metallo-β-lactamase motifs of both CPSF73 and CPSF100 are required for the endonuclease activity that cleaves histone pre-mRNAs, indicating that CPSF73 and CPSF100 act together (analogous to homodimeric RNase Z/J family members) to form the active endonuclease. In vitro point mutagenesis of conserved MBL residues in mammalian CPSF73 and CPSF100, histone pre-mRNA cleavage assay EMBO reports High 18688255
2008 CPSF-73 functions as a 5'-3' exonuclease that degrades the downstream cleavage product (DCP) of histone pre-mRNA in a U7 snRNP-dependent manner; degradation requires the U7 snRNP only for initiation and is processive. UV-crosslinking showed CPSF-73 directly contacts the DCP. RNAi showed that Xrn2 is not required for DCP degradation in vivo, implicating CPSF-73 as the in vivo 5'-3' exonuclease. UV-crosslinking with modified RNA substrates, in vitro degradation assay with U7 snRNP, RNAi knockdown of Xrn2 in HeLa cells Molecular and cellular biology High 18955505
2012 The N-terminal regions of FLASH and Lsm11 form a platform that recruits a specific combination of polyadenylation factors—symplekin, CstF64, and all CPSF subunits including CPSF73—to the U7 snRNP. This interaction is abolished by point mutations in FLASH that are detrimental for processing. The same polyadenylation factors are associated with endogenous U7 snRNP and are recruited to histone pre-mRNA in a U7-dependent manner. Co-immunoprecipitation, pulldown assays, mass spectrometry, point mutagenesis of FLASH/Lsm11, chromatin association assays Molecular and cellular biology High 23071092
2018 CPSF73 endonuclease activity is required for efficient transcriptional termination of protein-coding genes by RNA Pol II. Catalytically inactive CPSF73 cannot restore termination to cells lacking functional CPSF73, placing RNA cleavage by CPSF73 upstream of Xrn2-mediated cotranscriptional degradation and termination. CPSF73 loss causes more extensive readthrough transcription than Xrn2 elimination, indicating CPSF73 has a more foundational role. Conditional depletion via gene editing (auxin-inducible degron), catalytic mutant rescue experiments, mammalian native elongating transcript sequencing (mNET-seq) genome-wide Genes & development High 29432121
2008 CSR1 (a tumor suppressor) binds the C-terminus of CPSF3 (amino acids 440–543) via yeast two-hybrid and further direct binding assays. This interaction causes CPSF3 translocation from the nucleus to the cytoplasm, inhibiting polyadenylation activity both in vitro and in vivo. A CSR1 mutant unable to bind CPSF3 neither re-localizes it nor inhibits polyadenylation. CPSF3 knockdown by siRNA mimics CSR1-induced cell death. Yeast two-hybrid, co-immunoprecipitation, subcellular fractionation/localization, in vitro and in vivo polyadenylation assay, siRNA knockdown Oncogene Medium 18806823
2006 The C-terminal domain of yeast Brr5/Ysh1 (CPSF3 ortholog) lying outside β-lactamase homology is essential for cell viability and mRNA 3'-end processing. A homologous protein Syc1, by mimicking the essential Brr5 C-terminus, acts as a negative regulator of mRNA 3'-end formation. Yeast genetics (deletion analysis), in vitro 3'-end processing assay with yeast extracts, genetic rescue experiments RNA (New York, N.Y.) Medium 16431986
2019 CPSF3 is the direct molecular target of JTE-607 (a prodrug converted by ester hydrolysis to its active form), which binds CPSF3 as identified by compound-immobilized affinity chromatography. JTE-607 treatment causes accumulation of pre-mRNAs, and CPSF3 knockdown similarly causes pre-mRNA accumulation and suppresses inflammatory cytokine expression. Compound-immobilized affinity chromatography, CPSF3 knockdown, pre-mRNA accumulation assay Biochemical and biophysical research communications Medium 31399191
2019 CPSF3 is the target of JTE-607 in AML and Ewing's sarcoma. Chemical genetics/phenotypic screening identified CPSF3. Inhibition of CPSF3 prevents release of newly synthesized pre-mRNAs and causes transcriptional readthrough and formation of DNA-RNA R-loop structures. Phenotypic screening, chemical genetics, gene editing resistance mutations, pre-mRNA accumulation assays, R-loop detection Nature chemical biology High 31819276
2019 Crystal structures of Cryptosporidium CPSF3 reveal that the oxaborole AN3661 blocks mRNA processing activity by binding at the metal-dependent catalytic center of CPSF3, with the oxaborole group directly occupying the active site. X-ray crystallography of recombinant Cryptosporidium CPSF3 with inhibitor bound, growth inhibition assay, in vivo efficacy in mouse models Science translational medicine High 31694928
2020 Reconstituted recombinant U7 snRNP (all 13 components) demonstrates that CPSF73 is both an endonuclease and a 5'-3' exonuclease: it cleaves histone pre-mRNAs endonucleolytically and degrades the downstream cleavage product 5'-to-3'. Both activities require base-pairing of U7 snRNA, presence of the symplekin N-terminal domain (NTD), and are abolished by active-site mutations in CPSF73. Binding of symplekin NTD to SSU72 phosphatase also abolishes activity. In vitro reconstitution of recombinant U7 snRNP from 13 components, endonuclease and exonuclease assays, active-site mutagenesis of CPSF73, substrate modification studies RNA (New York, N.Y.) High 32554553
2020 In yeast, the Ysh1 (CPSF3 ortholog) endonuclease is regulated by ubiquitin-mediated proteasomal degradation. Ubiquitination of Ysh1 is mediated by the Ubc4 ubiquitin-conjugating enzyme and the RING ubiquitin ligase Mpe1. Ipa1 mutation causes striking depletion of Ysh1 protein (but not mRNA), rescued by proteasome inactivation or YSH1 overexpression. Yeast genetics (ipa1-1 mutant), proteasome inhibition, ubiquitination assays, YSH1 overexpression rescue, mRNA level analysis RNA biology Medium 32009536
2019 Yeast Ipa1 interacts with the Ysh1 (CPSF3 ortholog) endonuclease and promotes proper transcription termination and poly(A) site selection globally. Ipa1 mutation leads to decreased Ysh1 levels and poor recruitment of the cleavage/polyadenylation complex to transcribed genes. Ysh1 overexpression in the Ipa1 mutant rescues the termination defect. Chromatin immunoprecipitation, yeast genetic suppression (Ysh1 overexpression rescue), Pol II elongation kinetics assay Cell reports Medium 30759400
2021 UBE3D, a HECT-like E3 ligase, stabilizes CPSF73 protein by preventing its ubiquitin-mediated proteasomal degradation. Depletion of UBE3D leads to CPSF73 downregulation, a pre-mRNA cleavage defect, and dysregulated gene expression. UBE3D depletion, ubiquitination assay, pre-mRNA cleavage assay, protein stability assay iScience Medium 35992060
2023 X-ray crystallography demonstrated that benzoxaborole compounds bind to the active site of CPSF3 in a manner distinct from other known CPSF3 inhibitors. Forward genetics resistance mapping identified CPSF3 mutations that reduce benzoxaborole binding and confer resistance. Benzoxaboroles inhibit CPSF73 endonuclease activity in vitro and curb transcriptional termination in cells. X-ray crystallography of CPSF3-benzoxaborole complex, forward genetics resistance screen, in vitro endonuclease activity assay, transcription termination assay in cells Cell chemical biology High 37967558
2023 The C-terminal domain 3 (CTD3) of CPSF73 is required for binding to Symplekin, as demonstrated by biochemical assays; the CPSF73-CPSF100 C-terminal heterodimer structure was determined by NMR for the Encephalitozoon cuniculi minimal construct, revealing extensive inter-protein contacts and TBP-like CTD2 folds. NMR solution structure of minimal CPSF73-CPSF100 C-terminal heterodimer, biochemical binding assays (CTD3–Symplekin interaction) Open biology Medium 37989222
2023 The active site of CPSF73 contains a mixture of metal ions (Fe, Zn, Mn) rather than exclusively zinc ions. The abundance of the metal ions varies with the expression host, yet the enzyme retains endonuclease activity with less than 20% zinc occupancy, indicating that iron and/or manganese can support catalysis. Inductively coupled plasma mass spectrometry (ICP-MS), X-ray diffraction metal anomalous scattering, in vitro pre-mRNA cleavage assay The Journal of biological chemistry High 36822327
2024 UBE3D is a binding partner and stabilizer of CPSF73 in the cytoplasm; structural studies showed that the conserved C-terminal cysteine of UBE3D likely coordinates the active-site metal ions of CPSF73, functioning as a cytoplasmic chaperone required for CPSF73's nuclear pre-mRNA processing function. Loss of UBE3D leads to CPSF73 downregulation. Structural studies (cryo-EM of INTS9-INTS11-BRAT1 complex providing mechanistic analogy), co-immunoprecipitation, depletion experiments with pre-mRNA processing readout Molecular cell Medium 39032490
2024 RBBP6 E3 ligase mediates K63-linked ubiquitination of CPSF3, which stabilizes CPSF3 and regulates alternative polyadenylation events. RBBP6 depletion induces shortening of 3'UTRs of MYC competing-endogenous RNAs, releasing miR-590-3p to decrease MYC expression in glioblastoma stem cells. CRISPR/Cas9 knockout screens, Co-immunoprecipitation, ubiquitination assay (K63-linkage), 3'UTR sequencing, alternative polyadenylation profiling, CPSF3 inhibitor (JTE-607) functional assay Cell discovery Medium 38503731
2025 UBE3D interacts with CPSF3 and can de-ubiquitinate CPSF3; deficiency of UBE3D leads to reduced CPSF3 protein levels in both mouse and human cells. Overexpression of dominant negative CPSF3 mutants partially reduces mRNA levels of Homeobox genes, linking CPSF3-mediated pre-mRNA 3'-end processing to Homeobox gene expression during early embryogenesis. Co-immunoprecipitation, CRISPR/Cas9 knockout mice, in situ hybridization, immunofluorescence, RNA-seq, dominant-negative CPSF3 overexpression Cell death discovery Medium 40075082
2026 A conserved helix in the Lsm11 N-terminal extension directly contacts the metallo-β-lactamase domain of CPSF73 and is required to hold CPSF73 in the correct position for the cleavage reaction in U7 snRNP. Cryo-EM also revealed that CPSF73 can achieve an open (active) conformation independent of RNA binding in its active site. Additionally, the C-terminal end of CstF77 contacts CPSF100 at the CPSF73-CPSF100 interface, with a small effect on cleavage activity. Cryo-EM structure determination of reconstituted U7 snRNP complexes, mutagenesis/deletion of Lsm11 helix, in vitro pre-mRNA cleavage assays Nucleic acids research High 41495886
2026 Heat shock causes loss of CPSF73 endonucleolytic cleavage activity at thousands of genes despite CPSF73 remaining present. Overexpression of RBBP6, an activator of CPSF73, during heat shock rescues the loss of cleavage and dampens readthrough transcription. Heat shock also increases Tyr1 and Ser2 phosphorylation of the Pol II CTD at 3'-ends, which is attenuated at readthrough genes. mNET-seq or equivalent nascent RNA sequencing, overexpression rescue of RBBP6, cleavage assay, ChIP for Pol II CTD phosphorylation marks Cell reports Medium 41758649

Source papers

Stage 0 corpus · 42 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 Polyadenylation factor CPSF-73 is the pre-mRNA 3'-end-processing endonuclease. Nature 358 17128255
2005 The polyadenylation factor CPSF-73 is involved in histone-pre-mRNA processing. Cell 179 16213211
2004 Evidence that polyadenylation factor CPSF-73 is the mRNA 3' processing endonuclease. RNA (New York, N.Y.) 145 15037765
2009 A core complex of CPSF73, CPSF100, and Symplekin may form two different cleavage factors for processing of poly(A) and histone mRNAs. Molecular cell 107 19450530
2018 Xrn2 accelerates termination by RNA polymerase II, which is underpinned by CPSF73 activity. Genes & development 103 29432121
2019 LncRNA CASC9 interacts with CPSF3 to regulate TGF-β signaling in colorectal cancer. Journal of experimental & clinical cancer research : CR 92 31186036
2005 A CPSF-73 homologue is required for cell cycle progression but not cell growth and interacts with a protein having features of CPSF-100. Molecular and cellular biology 85 15684398
2012 A complex containing the CPSF73 endonuclease and other polyadenylation factors associates with U7 snRNP and is recruited to histone pre-mRNA for 3'-end processing. Molecular and cellular biology 71 23071092
2019 CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma. Nature chemical biology 68 31819276
2008 Conserved motifs in both CPSF73 and CPSF100 are required to assemble the active endonuclease for histone mRNA 3'-end maturation. EMBO reports 66 18688255
2008 Studies of the 5' exonuclease and endonuclease activities of CPSF-73 in histone pre-mRNA processing. Molecular and cellular biology 55 18955505
2019 Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection. Science translational medicine 51 31694928
2008 CSR1 induces cell death through inactivation of CPSF3. Oncogene 42 18806823
2012 Archaeal β-CASP ribonucleases of the aCPSF1 family are orthologs of the eukaryal CPSF-73 factor. Nucleic acids research 39 23222134
2019 JTE-607, a multiple cytokine production inhibitor, targets CPSF3 and inhibits pre-mRNA processing. Biochemical and biophysical research communications 32 31399191
2020 Target Identification of an Antimalarial Oxaborole Identifies AN13762 as an Alternative Chemotype for Targeting CPSF3 in Apicomplexan Parasites. iScience 30 33336164
2020 FttA is a CPSF73 homologue that terminates transcription in Archaea. Nature microbiology 29 32094586
2006 The role of the Brr5/Ysh1 C-terminal domain and its homolog Syc1 in mRNA 3'-end processing in Saccharomyces cerevisiae. RNA (New York, N.Y.) 23 16431986
2020 Studies with recombinant U7 snRNP demonstrate that CPSF73 is both an endonuclease and a 5'-3' exonuclease. RNA (New York, N.Y.) 22 32554553
2021 Dynamics of alternative splicing during somatic cell reprogramming reveals functions for RNA-binding proteins CPSF3, hnRNP UL1, and TIA1. Genome biology 20 34082786
2022 Targeting the mRNA endonuclease CPSF73 inhibits breast cancer cell migration, invasion, and self-renewal. iScience 19 35992060
2023 Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer. Science advances 16 37992178
2024 CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone mRNA processing. RNA (New York, N.Y.) 14 38191171
2024 RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation. Cell discovery 14 38503731
2023 Anticancer benzoxaboroles block pre-mRNA processing by directly inhibiting CPSF3. Cell chemical biology 12 37967558
2021 A real-time fluorescence assay for CPSF73, the nuclease for pre-mRNA 3'-end processing. RNA (New York, N.Y.) 10 34230059
2020 Regulation of the Ysh1 endonuclease of the mRNA cleavage/polyadenylation complex by ubiquitin-mediated degradation. RNA biology 9 32009536
2019 Ipa1 Is an RNA Polymerase II Elongation Factor that Facilitates Termination by Maintaining Levels of the Poly(A) Site Endonuclease Ysh1. Cell reports 9 30759400
2024 Cytoplasmic binding partners of the Integrator endonuclease INTS11 and its paralog CPSF73 are required for their nuclear function. Molecular cell 8 39032490
2023 An examination of the metal ion content in the active sites of human endonucleases CPSF73 and INTS11. The Journal of biological chemistry 8 36822327
2022 Population-level deficit of homozygosity unveils CPSF3 as an intellectual disability syndrome gene. Nature communications 8 35121750
2023 CPSF3 Promotes Pre-mRNA Splicing and Prevents CircRNA Cyclization in Hepatocellular Carcinoma. Cancers 7 37627085
2024 CPSF3 regulates alternative polyadenylation of CNIH2 to promote esophageal squamous cell carcinoma progression. Cancer letters 5 38718887
2023 Molecular details of the CPSF73-CPSF100 C-terminal heterodimer and interaction with Symplekin. Open biology 3 37989222
2023 1H, 15N and 13C resonance assignments of a minimal CPSF73-CPSF100 C-terminal heterodimer. Biomolecular NMR assignments 1 36723825
2026 An N-terminal helix of Lsm11 stabilizes CPSF73 in U7 snRNP for histone pre-mRNA 3'-end processing. Nucleic acids research 0 41495886
2026 CPSF73 activation and 3' RNA polymerase II pausing are lost during readthrough transcription after heat shock. Cell reports 0 41758649
2026 Acoziborole resistance associated mutations in Trypanosoma brucei CPSF3. PLoS pathogens 0 41774758
2026 Targeting CPSF73, the mRNA 3' End Processing Endonuclease, Moves Cancer Cells Away from the Mesenchymal State. bioRxiv : the preprint server for biology 0 41846976
2026 Small molecule inhibition of CPSF3 may impact R-loop distribution and abundance. Bioorganic & medicinal chemistry letters 0 42214474
2025 Deficiency of UBE3D in mice leads to severe embryonic abnormalities and disrupts the mRNA of Homeobox genes via CPSF3. Cell death discovery 0 40075082
2025 Small molecule inhibition of CPSF3 impacts R-loop distribution and abundance. bioRxiv : the preprint server for biology 0 40654756

Missed literature

Know a paper Affinage missed for CPSF3? Flag it for the maintainers and the community.

No submissions yet.